UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1028 - 1029
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Female | Male | Drug Resistance, Neoplasm - drug effects | Relapse | Multiple myeloma | Diseases | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 10/2014, Volume 124, Issue 14, pp. 2162 - 2163
Life Sciences & Biomedicine | Hematology | Science & Technology | Protein Kinase Inhibitors - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Multiple Myeloma - drug therapy | Pyrazoles - administration & dosage | Humans | Female | Male | Thiophenes - administration & dosage | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
Bone marrow transplantation (Basingstoke), ISSN 0268-3369, 01/2021, Volume 56, Issue 1, pp. 210 - 217
Immunology | Life Sciences & Biomedicine | Hematology | Oncology | Transplantation | Biophysics | Science & Technology | Care and treatment | Diagnosis | Patient outcomes | Stem cells | Multiple myeloma | Confidence intervals | Autografts | Abnormalities | Stem cell transplantation | Survival | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | South America | Recurrence | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Pyrazines - administration & dosage | Boronic Acids - adverse effects | Male | Multiple Myeloma - ethnology | Antineoplastic Agents - administration & dosage | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Injections, Subcutaneous | Aged, 80 and over | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Boronic Acids - administration & dosage | Blood Cells - drug effects | Multiple Myeloma - blood | Bortezomib | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Multiple Myeloma - pathology | Asia | Pyrazines - adverse effects | Aged | Infusions, Intravenous | Neoplasm Staging | Medical colleges | Medical research | Relapse | Multiple myeloma | Medicine, Experimental | Diseases | Index Medicus
Journal Article
Thrombosis research, ISSN 0049-3848, 2012, Volume 130, Issue 1, pp. S63 - S65
Hematology, Oncology and Palliative Medicine | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Thromboembolism - chemically induced | Multiple Myeloma - mortality | Humans | Risk Factors | Multiple Myeloma - immunology | Treatment Outcome | Thromboembolism - mortality | Incidence | Multiple Myeloma - drug therapy | Thromboembolism - prevention & control | Fibrinolytic Agents - therapeutic use | Immunologic Factors - adverse effects | Practice Guidelines as Topic | Thrombosis | Blood clot | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 14, pp. 1311 - 1320
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Stem Cell Transplantation | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Maintenance Chemotherapy | Thalidomide - adverse effects | Dexamethasone - administration & dosage | Lenalidomide | Kaplan-Meier Estimate | Combined Modality Therapy | Thalidomide - administration & dosage | Disease-Free Survival | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bortezomib - adverse effects | Aged | Usage | Care and treatment | Bortezomib | Dexamethasone | Patient outcomes | Multiple myeloma | Transplantation of organs, tissues, etc | Dosage and administration | Autografts | Gastrointestinal tract diseases | Minimal residual disease | Stem cell transplantation | Peripheral neuropathy | Patients | Chemotherapy | Melphalan | Thromboembolism | Neutropenia | Index Medicus | Abridged Index Medicus | Life Sciences | Cancer
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 22, pp. 2104 - 2115
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Development and progression | Dosage and administration | Dexamethasone | Drug therapy | Multiple myeloma | Autografts | Pneumonia | Research & development--R&D | Minimal residual disease | Stem cell transplantation | Leukocytes | Evidence-based medicine | Chemotherapy | Lymphopenia | Risk assessment | Death | Neutropenia | Medicin och hälsovetenskap
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 19, pp. 1811 - 1822
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Development and progression | Usage | Dexamethasone | Drug therapy | Multiple myeloma | Immunostimulation | Immunomodulation | Clinical trials | Patients | Survival | Evidence-based medicine | Proteasome inhibitors | Hyperglycemia | Chemotherapy | Medical prognosis | Response rates | Monoclonal antibodies | Drug dosages | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1782 - 1791
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Bone marrow, stem cells transplantation. Graft versus host reaction | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Young Adult | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Chemotherapy | Consolidation | Transplants & implants | Clinical trials | Stem cell transplantation | Peripheral neuropathy | Patients | Drug dosages | Index Medicus | Abridged Index Medicus | Antineoplastic Agents | Life Sciences | Neoplasms, Second Primary | Thalidomide | Multiple Myeloma | Cancer
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 16, pp. 1953 - 1959
Life Sciences & Biomedicine | Oncology | Science & Technology | Immunopathology | Biological and medical sciences | Immunoglobulinopathies | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Tumors | Recurrence | Dexamethasone - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thalidomide - administration & dosage | Disease Progression | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Aged | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 07/2020, Volume 396, Issue 10245, pp. 186 - 197
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carfilzomib | Relapse | Care and treatment | Dexamethasone | Multiple myeloma | Diseases | Randomization | Bortezomib | Risk assessment | Antibodies | Bone marrow | Safety | Survival | Ejection fraction | Index Medicus | Abridged Index Medicus
Journal Article